Solid-tumor treatment method

• US 5,527,528 A
• Filed: 03/31/1993
• Issued: 06/18/1996
• Est. Priority Date: 10/20/1989
• Status: Expired due to Term

• Current Assignee: SEQUUS Pharmaceuticals, Inc. (Johnson & Johnson)
• Original Assignee: SEQUUS Pharmaceuticals, Inc. (Johnson & Johnson)
• Inventors: Martin, Francis J., Allen, Theresa M.
• Primary Examiner(s): Parr, Margaret
• Assistant Examiner(s): EISENSCHENK, FRANK C
• Application Number:
  US08/040,544
• Time in Patent Office: 1,175 Days
• Field of Search: 424/85.8, 424/450, 424/181.1, 424/812, 424/178.1
• US Class Current: 424/178.1
• CPC Class Codes: A61K 47/6911 the form being a liposome
• CPC Class Codes: A61K 47/6913 the liposome being modified on its surface by an antibody
• CPC Class Codes: A61K 9/1271 Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers liposome as conjugate A61K47/6911
• CPC Class Codes: C07F 9/5537 the heteroring containing the structure -C(=O)-N-C(=O)- (both carbon atoms belong to the heteroring)
• CPC Class Codes: Y10S 424/812 Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector

Abstract

A method of administering an anti-tumor compound to a subject is disclosed. The method includes administering to a subject liposomes having sizes predominantly in the range 0.05 to 0.12 microns, and containing an anti-tumor compound in liposome-entrapped form, a surface coating of polyethylene glycol chains, at a surface concentration thereof sufficient to extend the blood circulation time of the liposomes severalfold over that of liposomes in the absence of such coating, and surface-attached antibody molecules effective to bind specifically to tumor-associated antigens present at the tumor site. One liposome composition includes doxorubicin in entrapped form, and, on the liposome surface, a monoclonal antibody against highly proliferating cells in a lung squamous cell carcinoma.

Claims

1. A method of administering an anti-tumor compound to a subject, for solid tumor treatment, comprising

administering to the subject, by parenteral injection, liposomes having sizes in the range of 0.05 to 0.12 microns, and containing an anti-tumor compound in liposome-entrapped form, a surface coating of polyethylene glycol chains at a surface concentration thereof sufficient to extend the blood circulation time of the liposomes severalfold over that of liposomes in the absence of such coating, and antibodies or antibody fragments effective to bind specifically to tumor-associated antigens,

wherein the polyethylene glycol chains contain, in a portion thereof, functionalized reactive groups at their free ends to which said antibodies or antibody fragments are covalently attached.

2. The method of claim 1, wherein said tumor cells are squamous carcinoma cells localized in the lung.